SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
SARS-CoV-2 from alpha to epsilon: As battles to contain the COVID-19 pandemic continue, attention is focused on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that have been deemed variants of concern because they are resistant to antibodies elicited by infection or vaccination or they increase transmissibility or disease severity. Three papers used functional and structural studies to explore how mutations in the viral spike protein affect its ability to infect host cells and to evade host immunity. Gobeil et al . looked at a variant spike protein involved in transmission between minks and humans, as well as the B1.1.7 (alpha), B.1.351 (beta), and P1 (gamma) spike variants; Cai et al . focused on the alpha and beta variants; and McCallum et al . discuss the properties of the spike protein from the B1.1.427/B.1.429 (epsilon) variant. Together, these papers show a balance among mutations that enhance stability, those that increase binding to the human receptor ACE2, and those that confer resistance to neutralizing antibodies. —VV
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2. B.1.427/B.1.429 S pseudotyped virus neutralization by vaccine-elicited and COVID-19 convalescent plasma. (A, B, E, and F) Neutralizing Ab titers [mean inhibition dilution (ID50)] shown as pairwise connected [(A) and (E)] or GMT [(B) and (F)] against MLV [(A) and (B)] or VSV [(E) and (F)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Moderna mRNA-1273 vaccine (blue). (C, D, G, and H) Neutralizing Ab titers (ID50) shown as pairwise connected [(C) and (G)] or GMT [(D) and (H)] against MLV [(C) and (D)] or VSV [(G) and (H)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine (red). (I and J) Neutralizing Ab ID50 (I) and GMT (J) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from naïve (blue) and previously infected (red) individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine. “Naïve” indicates vaccinated individuals who had not been previously infected with SARS-CoV-2; “immune” refers to vaccinated individuals who had been previously infected with SARS-CoV-2. (K and L) Neutralizing Ab ID50 (K) and GMT (L) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from convalescent individuals who were infected with WT SARS-CoV-2. Neutralization data shown in (A) to (H) and (I) to (L) were performed using 293T-ACE2 and VeroE6-TMPRSS2, respectively. Data are average of n = 2 replicates.](https://figures.cochat.ai/paper-figures/e2b6f8f874fc4753bb3a1e70b39ac8ee/sars-cov-2-immune-evasion-by-the-b-1-427-b-1-429-variant-of-concern-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This signal peptide modification resulted in a total loss of neutralization by ten NTD-specific antibodies [40].”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of 34 convalescent plasma samples from persons infected with the Alpha variant, 59% had 3-fold to 10-fold reduced neutralizing activity and 18% had >10-fold reduced neutralizing activity to the Beta variant 99,104,221 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [221]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A novel mechanism of immune evasion was studied in the Epsilon variant, where the other two mutations remodeled NTD by shifting the signal peptide cleavage site in the NTD antigenic supersite and forming a new disulfide bond.”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Self-citationLiebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 7,953
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267
New tools for automated high-resolution cryo-EM structure determination in RELION-3
Zivanov, J., Nakane, T., Forsberg, B. O., Kimanius, D., Hagen, W. J., Lindahl, E., & Scheres, S. H. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,621
Cited by
Items 401–426 of 426
Advancements in Structural Basis of Covalent Inhibitors Targeting SARS-CoV-2 Essential Proteins
Fatima, I., Alshabrmi, F. M., Alkhayl, F. F. A., Qasim, M., Shafqat, A., Batool, S., Jawad, M. T., Qamar, M. T. U., & Rehman, A. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673323348241208080419
SARS-CoV-2 spike protein in infectivity
Altaie, A. M., Hamdy, R., Husseiny, M. I., & Soliman, S. S. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00015-2
Guilbaud, R., Maiga, A. I., Ouédraogo, A., Sawadogo, Y., Niama, F. R., Mahamat, O. O., Toni, T. D., Kabo, A. K., Mayengué, P. I., Koukouikila-Koussounda, F., et al. (2026) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2026.103334
A High-Resolution Approach to Mapping Spike Protein Evolution for Advancing Antibody Therapy DesignPreprint
Bhatti (2025) · Research Square · doi:10.21203/rs.3.rs-7753519/v1
Coronaviruses in human pathophysiology: a brief history of the COVID-19 pandemic
Vlasov, I. N., Shadrina, M. I., & Slominsky, P. A. (2025) · Molecular Genetics Microbiology and Virology (Russian) · doi:10.17116/molgen20254304255
Additional file 3 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555534
Additional file 7 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555546
Additional file 10 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555555
Additional file 9 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555552
Additional file 6 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555543
Additional file 4 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555537
Additional file 8 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555549
Additional file 1 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555528
Additional file 2 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555531
Additional file 5 of Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26555540
Wang, F., Huang, B., Deng, Y., Zhang, S., Liu, X., Wang, L., Liu, Q., Zhao, L., Tang, L., Wang, W., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23621392
Jaiswal, D., Altomare, C. G., Adelsberg, D. C., Sapse, I. A., Singh, G., Krammer, F., Simon, V. R., Ellebedy, A. H., & Bajic, G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.03.709398
Coronaviruses in Human Pathophysiology: a Brief History of the COVID-19 Pandemic
Vlasov, I. N., Shadrina, M. I., & Slominsky, P. A. (2025) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416825700326
Jaiswal, D., Altomare, C. G., Adelsberg, D. C., Sapse, I. A., Krammer, F., Simon, V. R., Ellebedy, A. H., & Bajic, G. (2026) · eLife · doi:10.7554/elife.111137
Jaiswal, D., Altomare, C. G., Adelsberg, D. C., Sapse, I. A., Krammer, F., Simon, V. R., Ellebedy, A. H., & Bajic, G. (2026) · eLife · doi:10.7554/elife.111137.1
Altaf, M., Cheng, M. T. K., González-Vázquez, L. D., Jesu Castin, E., Kemp, S. A., Hisner, R., Martin, D. P., Thukral, L., Meng, B., & Gupta, R. K. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117460 · Cited by 1
石渡さおり, Tanimoto, K., Tanaka, Y., Sassa, C. T., Takahashi, Y., Sonobe, K., Tohda, S., Sukegawa, S., Kimura, A., Gu, Y., et al. (2026) · PNAS Nexus · doi:10.1093/pnasnexus/pgag191
“This result includes experimentally validated mutations such as L452R in the spike protein, which confers increased transmissibility and infectivity, and reduced sensitivity to neutralizing antibodies (18, 19).”
Systems-Scale Structural Modeling Reveals the Germline Architecture of ImmunodominancePreprint
Shrock, E. L., Sun, E., Dhindsa, A., Witwer, M. H., Yu, Z., Ivanochko, D., Lee, I., Coventry, B., Gonzalez, M. B., Julien, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.02.729678 · Cited by 1
Protective activity of mRNA vaccines
Krammer, F. (2024) · ImmPort · doi:10.21430/m3nt600qa9
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · doi:10.1101/2021.03.07.21252647 · Cited by 651
Metadata
- Authors
- McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., Sprouse, K. R., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., Guastalla, S. B., Bona, G., Pellanda, A. F., Garzoni, C., Van Voorhis, W. C., Rosen, L. E., Snell, G., Telenti, A., Virgin, H. W., Piccoli, L., Corti, D., & Veesler, D.
- Affiliations
- University of Washington (US)
- Vir Biotechnology (Switzerland) (CH)
- Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
- VIR Biotechnology (United States) (US)
- Vir Biotechnology, San Francisco, CA 94158, USA.
- Independent physician, 6828 Balerna, Switzerland.
- Clinica Luganese Moncucco (CH)
- Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
- Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
- Corresponding author
- McCallum, Matthew
- Bassi, Jessica
- Chen, Alex
- Walls, Alexandra C.
- Piccoli, Luca
- Corti, Davide
- Veesler, David
- ORCID
- McCallum, Matthew
- Bassi, Jessica
- De Marco, Anna
- Chen, Alex
- Walls, Alexandra C.
- Di Iulio, Julia
- Tortorici, M. Alejandra
- Navarro, Mary-Jane
- Saliba, Christian
- Sprouse, Kaitlin R.
- Pinto, Dora
- Culap, Katja
- Bianchi, Siro
- Jaconi, Stefano
- Cameroni, Elisabetta
- Bowen, John E.
- Tilles, Sasha W.
- Pizzuto, Matteo Samuele
- Guastalla, Sonja Bernasconi
- Bona, Giovanni
- Pellanda, Alessandra Franzetti
- Garzoni, Christian
- Van Voorhis, Wesley C.
- Rosen, Laura E.
- Snell, Gyorgy
- Telenti, Amalio
- Virgin, Herbert W.
- Piccoli, Luca
- Corti, Davide
- Veesler, David
- Venue
- Science
- Published
- 2021-08-06
- Volume
- 373
- Issue
- 6555
- Pages
- 648-654
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9835956
- OpenAlex
- W3174747632
- Cited by
- 412
- References
- 90
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 25 · 2023: 56 · 2022: 165 · 2021: 141
- FWCI
- 31.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (DP1AI158186, HHSN272201700059C, U01 AI151698-01)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, immune evasion, spike protein mutations, L452R, N-terminal domain, receptor binding domain, neutralizing antibodies, monoclonal antibodies, signal peptide cleavage site, disulfide bonds, mRNA vaccines, convalescent plasma, neutralization titers
- MeSH terms
- Protein Domains, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Antibodies, Monoclonal, Antibodies, Viral, Antigens, Viral, Humans, Models, Molecular, Mutation, Neutralization Tests, Protein Conformation, Amino Acid Substitution, Cryoelectron Microscopy, Protein Subunits, Protein Interaction Domains and Motifs, Immune Evasion, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.